Mode
Text Size
Log in / Sign up
N/A N=47 Randomized Double-blind Treatment

Estrogen and Serotonin on Changing Brain Chemistry

Menopause

Enrolled (actual)
47
Serious AEs
0.0%
Results posted
Apr 2021
Primary outcome: Primary: Percent Change in BOLD Signal — -.43; .20 percentage of BOLD signal changes

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
estrogen patch (Drug); Amino acids (Drug); Placebo Patch (Drug); Placebo pills (Drug)
Age
Adult · 48+ yrs
Sex
Female
Sponsor
University of Colorado, Denver
Primary completion
Nov 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent Change in BOLD Signal
-.43; .20
SECONDARY
Evaluate the Changes in Verbal Working Memory Mediated Through the Dorsolateral Prefrontal Cortex.

Summary

The aim of this study is to examine the effects of estrogen and serotonin on cognition, emotional processing, and brain activation. The investigators will study the effects of acute tryptophan (TRP) depletion on cognition and mood in healthy menopausal women before and after estrogen replacement treatment (ERT). Using functional magnetic resonance imaging (fMRI), the investigators will identify differences in brain activation during memory tasks with and without TRP depletion and before and after estrogen therapy in order to determine which brain regions and cognitive functions are affected by each manipulation.

Eligibility Criteria

Key Inclusion Criteria

Women ages 48 to 60 (at the time of enrollment) will be eligible for this study if they:

  • Have no history of major depressive disorder, generalized anxiety disorder, and or panic disorder within the last three years according to the Structured Clinical Interview for DSM-IV (Diagnostic and Statistical Manual) Axis I Disorders (SCID-NP) (First et al., 1995), or a history of major depressive disorder, generalized anxiety disorder, and or panic disorder greater than 3 years ago, but now resolved according to the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-NP) (First et al., 1995);
  • Have no substance abuse disorders (this includes alcohol, prescription, and illicit substances) within the last three years according to the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-NP) (First et al., 1995);
  • Subject has history of substance abuse disorders (this includes alcohol, prescription, and illicit substances) >3 years ago but the period of abuse did not last more than 5 years according to the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-NP) (First et al., 1995);
  • No first-degree relative (excluding children) with a known psychotic disorder or bi-polar disorder per patient report. Psychotic disorders include schizophrenia, schizoaffective disorder, psychotic disorder;
  • Have not taken hormonal contraceptives, ET (estrogen therapy) or HT (hormone therapy) for at least 3 months as per self-report;
  • Are within 10 years and 11 months of LMP (last menstrual period) as per self-report;
  • Have a follicular stimulating hormone level (FSH) of >30 IU/ml as per hormone testing results; women with an FSH below 30 will have the option to undergo an additional blood draw between 3-9 months following the initial blood draw (see note 2 below);
  • Are able to give written informed consent;
  • Provide written documentation of having had a normal mammogram and a PAP smear (Papanicolaou test) within the recommended timeframe as defined by the American College of Obstetricians and Gynecologists (ACOG) - please visit their website for current recommendations;
  • Must have clear urine toxicology screen upon recruitment;
  • Are fluent in written and spoken English;
  • Are right-handed.

Key Exclusion Criteria

  • Currently smoking more than 10 cigarettes/day by self report;
  • History of clinical CVD (cardiovascular disease) including myocardial infarction, angina, or congestive heart failure;
  • History of thromboembolic disease (deep vein thrombosis or pulmonary embolus);
  • History of untreated (no cholecystectomy) gallbladder disease as per self-report during PE;
  • History of triglyceridemia by subject report;
  • Undiagnosed vaginal bleeding as per self-report;
  • History of estrogen responsive cancers as per self-report;
  • Known hypercoagulable state (thrombophilias) as per self-report;
  • Severe lactose intolerance (sham depletion requires lactose/microcellulose administration; mild to moderate lactose intolerance is acceptable); Dr. Epperson will make the final decision whether an individual's lactose intolerance is severe enough to require exclusion;
  • Use of estrogen- or progestin-containing medication or phytoestrogen containing supplements (e.g. soy concentrates or extracts) within 3 months of participation as per self-report; foods containing soy (e.g. tofu, soy milk) will be permissible; estrogen-based localized treatments such as creams and vaginal inserts will be permissible, so long as said treatments do not effect systemic estrogen levels (women using localized treatments must have estrogen levels similar to other women in the study of their age and menopause status). PI will have final decision about enrollment (see note 3 below);
  • Have a Mini Mental Status Score of 14;
  • As per self-report, have taken a psychotropic medication within the previous month, with the exception of sleeping aids if the participant is willing to forgo use during st
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01208324). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search